Check out this morning's top movers from around Wall Street, compiled by The Fly.

HIGHER -

BiondVax (BVXV) up 10% after additional results in a preclinical in vivo proof-of-concept study of its inhaled nanosized antibody COVID-19 therapy, namely that the presence of the SARS-COV-2 virus in the lungs of hamsters treated with BiondVax's NanoAb was below detectable levels and significantly less than the amount of virus detected in the placebo group
Spruce Biosciences (SPRB) up 130% after entering into an exclusive licensing agreement for the development and commercialization of Spruce's product candidate, tildacerfont, for the treatment of congenial adrenal hyperplasia in Japan
CytomX Therapeutics (CTMX) up 72% after the company and Moderna (MRNA) announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody therapeutic platform

UP AFTER EARNINGS -

LOWER -

Tesla (TSLA) down 7% after The Wall Street Journal reported that the company is cutting the prices of its Model 3 and Model Y cars sold in China after deliveries of its cars plunged in December
Bed Bath and Beyond (BBBY) down another 12% after yesterday pre-announcing Q3 results and expressing doubts in the company's ability to continue as a going concern.
Southwest (LUV) down 2% after reporting preliminary Q4 results and noting that it expects to report a net loss in Q4
Novocure (NVCR) down 4% after Wells Fargo analyst Larry Biegelsen downgraded the stock to Equal Weight from Overweight with a price target of $107, up from $89
Fate Therapeutics (FATE) down 58% after declining a proposal from Johnson & Johnson (JNJ) unit Janssen Biotech for continuation of the collaboration and option agreement between the parties on revised terms and conditions and, as a result, the agreement has been terminated and all collaboration activities will be wound down in the first quarter of 2023